Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16PRNewsWire • 01/30/23
Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional RadiologyPRNewsWire • 01/17/23
Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4)PRNewsWire • 12/16/22
Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental MetastasisPRNewsWire • 12/05/22
Delcath Systems, Inc. (DCTH) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/08/22
Delcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022PRNewsWire • 09/01/22
Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/08/22
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/08/22
Delcath Systems Reports Second Quarter 2022 Results and Provides Business UpdatePRNewsWire • 08/08/22
Results of a Multicenter Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Cardiovascular and Interventional RadiologyPRNewsWire • 08/05/22
Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual MeetingGlobeNewsWire • 06/06/22
Delcath Systems Ltd. (DCTH) CEO Gerard Michel on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/10/22
Delcath Systems Reports First Quarter 2022 Results and Provides Business UpdateGlobeNewsWire • 05/10/22